DBS of the GPi and STN are well-established therapies of Parkinson’s disease, but outcomes on the very long-term are lacking. At the AAN 2021 meeting, extended long-term outcomes – of up to 10 years in some cases – from the landmark CSP468 VA/NINDS multicentre, randomised-controlled trial (NCT01076452) were presented [1].
A subset of patients originally randomised to GPi or STN DBS and with visits completed at 2 years were followed for up to 10 years. Data included analyses at baseline (GPi n=152; STN n=147), 2 years (GPi n=85; STN n=70), 7 years (GPi n=68; STN n=49), and 10 years (GPi n=49; STN n=28). The primary outcome was change in score of the Unified Parkinson’s Disease Rating Scale (UPDRS) part III (motor subscale) in the off medication/on stimulation state. At baseline, these scores were 43.2 in both groups.
Improvement in UPDRS motor scores was maintained across all times analysed, in both groups. In the STN group, the scores declined from 43.2 to 27.7 after 2 years (P<0.001), to 34.4 after 7 years (P<0.001), and to 28.3 after 10 years (P<0.001). In the GPi group, the scores were 25.8 after 2 years (P<0.001), 35.4 after 7 years (P<0.001), and 34.0 after 10 years (P=0.10). Improvements were generally similar over time, but with a trend favouring STN (P=0.09). Tremor subscales showed the greatest reduction, followed by rigidity. Bradykinesia subscores showed greater improvement at 7 and 10 years with STN DBS (P=0.03). The UPDRS I, II, and IV scores and quality of time based on motor diaries also demonstrated significant long-term improvements, regardless of target. The tremor subscales showed the greatest reduction over time, followed by rigidity subscores. Both targets had equal and significant medication reduction. Parkinson's Disease Questionnaire-39 (PDQ-39) total score no longer showed improvement at 7 or 10 years (either target).
The 4-year follow-up results of the INTREPID trial (NCT01839396) showed that use of a multiple-source, constant-current rechargeable DBS system is safe and effective for the long-term in patients with Parkinson’s disease [2]. INTREPID was a double-blinded, randomised, sham-controlled trial of a novel DBS device capable of Multiple Independent Current Control (MICC). Results of 120 patients showed continued improvement of the UPDRS part III in the off medication/on stimulation state (43.4 at baseline; 21.2 at 1 year; 22.6 at 2 years; 22.6 at 3 years; 25.6 at 4 years). Medication reductions were maintained, and PDQ-39 scores indicated ongoing improvements in most aspects of quality of life.
- Ostrem J, et al. 10 Year Clinical Outcomes of Subthalamic Nucleus versus Pallidal Deep Brain Stimulation for Parkinson’s Disease: VA/NINDS CSP #468F. S8.003, AAN 2021 Virtual Congress, 17-22 April.
- Vitek J, et al. Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson's Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT. S8.004, AAN 2021 Virtual Congress, 17-22 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis Next Article
Novel AAV-based gene therapy for Duchenne muscular dystrophy »
« Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis Next Article
Novel AAV-based gene therapy for Duchenne muscular dystrophy »
Table of Contents: AAN 2021
Featured articles
Letter from the Editor
Interview with AAN President Dr James C. Stevens
COVID-19 and Neurology
The neurological impact of COVID-19
Chemosensory dysfunction often persistent after COVID-19
Pandemic results in decreased global stroke care
Stroke uncommon in critically ill COVID-19 patients
Cognitive Impairment and Dementias
Obstructive sleep apnoea associated with lower cognition
NfL is a better marker for neurodegeneration than T-tau
Monoclonal antibody rapidly reduces brain amyloid
Epilepsy
Extraordinary transformation of epilepsy care in Ontario
No neurodevelopmental effects of foetal antiseizure medication
Migraine and Other Headaches
Long-term safety of atogepant as migraine prophylaxis
Multiple Sclerosis
Dysmetabolism may drive MS progression
Predicting long-term prognosis in paediatric MS patients
Neuromuscular Disorders
Functional and survival benefits of AMX0035 in ALS
Parkinson’s Disease and Other Movement Disorders
Autoimmune mechanisms implicated in Parkinson’s disease
Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis
Troriluzole for spinocerebellar ataxia
Stroke
Can linoleic acid help prevent stroke?
No association between SSRIs and risk of ICH
Other Topics
Vutrisiran for hATTR amyloidosis with polyneuropathy
10 kHz spinal cord stimulation for painful diabetic neuropathy
Related Articles
June 16, 2021
Tolebrutinib reduces brain lesions in very active MS
June 16, 2021
Extraordinary transformation of epilepsy care in Ontario
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy